Romosozumab Tops Denosumab in Treating GIOP

Table of Contents

TOPLINE:

Romosozumab (Evenity) is superior to denosumab (Prolia) in growing bone mineral density (BMD) in sufferers with glucocorticoid-induced osteoporosis (GIOP).

METHODOLOGY:

Romosozumab is a US Meals and Drug Administration-approved humanized monoclonal antibody used to deal with osteoporosis in postmenopausal girls with a excessive threat for facture.
The examine included 70 adults with GIOP with a high-risk for osteoporotic fracture who obtained a ≥5 mg/day prednisolone dose for no less than 12 months previous to the examine.
Sufferers have been randomly assigned to obtain romosozumab subcutaneously (210 mg) each month for 12 doses or denosumab subcutaneously (60 mg) each 6 months for 2 doses.
The first endpoint was the distinction in BMD on the lumber backbone from baseline to 1 yr.

TAKEAWAY:

Sufferers within the romosozumab group had a considerably better improve in backbone BMD (+7.3%) after 12 months, in contrast with these within the denosumab group (+2.3%).
Each teams had the same improve in hip BMD at 1 yr, whereas femoral neck BMD didn’t considerably improve in both group through the examine interval.
The romosozumab group had a decrease drop in serum C-terminal telopeptide of sort I collagen (CTX) however confirmed a rise in procollagen sort 1 N propeptide (P1NP), in contrast with the denosumab group.
Sufferers within the romosozumab extra regularly reported injection web site ache, erythema, and swelling.

IN PRACTICE:

“Romosozumab could supply a brand new remedy choice in GIOP in high-risk sufferers,” write the authors.

STUDY DETAILS:

Chi-Chiu Mok, MD, Tuen Mun Hospital, Hong Kong, led the analysis and introduced abstract OP0246 on June 2 on the European Alliance of Associations for Rheumatology (EULAR) 2023 Annual Assembly.